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Abstract
Inherent recipient factors, including pre-transplant diagnosis, obesity, and elevated pulmonary
pressures are established PGD risks. We evaluated the relationship between pre-operative lung
injury biomarkers and PGD to gain further mechanistic insight in recipients. We performed a
prospective cohort study of recipients in the lung transplant outcomes group enrolled between
2002 and 2010. Our primary outcome was grade 3 PGD on day 2 or 3. We measured pre-operative
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plasma levels of 5 biomarkers (CC-16, sRAGE, ICAM-1, IL-8, and Protein C) that were
previously associated with PGD when measured at the post-operative timepoint. We used
multivariable logistic regression to adjust for potential confounders. Of 714 subjects, 130 (18%)
developed PGD. Median CC-16 levels were elevated in subjects with PGD (10.1 vs. 6.0, p<0.001).
CC-16 was associated with PGD in non-IPF subjects (OR for highest quartile of CC-16: 2.87, 95%
CI: 1.37, 6.00, p=0.005) but not in subjects with IPF (OR 1.38, 95% CI: 0.43, 4.45, p=0.59). After
adjustment, pre-operative CC-16 levels remained associated with PGD (OR: 3.03, 95% CI: 1.26,
7.30, p=0.013) in non-IPF subjects. Our study suggests the importance of pre-existing airway
epithelial injury in PGD. Markers of airway epithelial injury may be helpful in pre-transplant risk
stratification in specific recipients.
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Introduction
Primary graft dysfunction (PGD) is a form of acute lung injury occurring within 72 hours of
lung transplantation (1, 2). It is the leading cause of early morbidity and mortality after
transplant (3, 4), yet the mechanisms driving the development of PGD remain unclear. Prior
work evaluating post-operative timepoints has identified plasma biomarkers associated with
concurrent PGD, including soluble receptor for advanced glycation end products (sRAGE),
club cell (Clara) secretory protein (CC-16), protein C, and intercellular adhesion molecule-1
(ICAM-1) (5–8). These markers have helped establish potential mechanisms occurring
during clinical PGD, and have demonstrated discriminant validity as a quantitative measure
of PGD (9). However, there is a lack of knowledge of mechanisms occurring prior to
transplant in the recipient that may be important in the development of PGD, and better pre-
operative recipient risk stratification may allow for changes in management or therapy prior
to transplantation to reduce the risk of PGD.
Recently, we and others have established several recipient-related clinical risk factors for
primary graft dysfunction, including obesity, presence of pulmonary hypertension, and
predisposing diagnosis (4). Identification of the biologic processes underlying these clinical
PGD associations is important because it will give insight into potentially modifiable factors
prior to transplantation. For example, although predisposing diagnosis is not modifiable
prior to transplantation, enhanced understanding of what is driving the increased risk of a
particular diagnosis may provide targets for therapy to decrease PGD risk prior to
transplantation. Additionally, studying biologic markers within known risk groups is
important as there are likely several different mechanisms contributing to the risk of PGD
and measurement of biomarkers may allow for individualized management decisions to
decrease PGD risk.
In order to further study potential mechanisms underlying previously established clinical
risk factors and identify potential biologic targets prior to transplantation to reduce the risk
of development of PGD, we tested the association between five known PGD lung injury
biomarkers measured pre-operatively in the recipient and the subsequent risk of
development of PGD.
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The Lung Transplant Outcomes Group (LTOG) cohort is a multi-center, prospective study
that has been previously described (5, 6). In prior studies, we have measured post-operative
biomarkers in smaller subsets of this cohort study (6–8). In this study, we measured five pre-
operative biomarkers in a large cohort of subjects that is expanded and distinct from
previously studied cohorts. We included subjects transplanted between July 2002 and May
2010 with at least one biomarker measurement at the pre-operative time point. The majority
of samples were collected immediately prior to transplantation during the transplant
admission, however, a fraction were collected at the time of listing. Samples were processed
within 60 minutes and then stored at −80° C for subsequent analysis, and clinical data were
collected prospectively for all subjects as described previously (5, 7, 10). Mortality
information was collected from each center and supplemented with data from UNOS (11).
IRB approval was obtained from each participating center. Informed consent was obtained
from each subject enrolled in the cohort.
Determination of PGD Grade
Our primary outcome was grade 3 PGD at 48 or 72 hours after transplantation. PGD grade
was determined using the ISHLT consensus definition (2, 10, 12). Two blinded physicians
examined chest radiographs to assess for the presence of PGD. Radiographs qualified for
PGD if the transplanted lung(s) had diffuse infiltrates. Radiographs and arterial blood gases
were assessed at the time of admission to the ICU after transplantation (T0), and 24, 48, and
72 hours after transplantation. The severity of PGD was graded according to the PaO2/FiO2
ratio, with a PaO2/FiO2 ratio less than 200 defining grade 3 PGD (13).
Measurement of sRAGE, ICAM-1, Protein C, IL-8, and CC-16
Biomarkers were chosen because of previously reported associations with acute lung injury
or PGD (5, 7, 14, 15). Protein C was measured using the Actichrome protein C assay
(American Diagnostica, Greenwich, CT). The intra-assay coefficient of variation was 5.5%.
sRAGE, ICAM-1, and IL-8 were measured by ELISA (R&D, Minneapolis, MN). The intra-
assay coefficients of variation were 7%, 5%, and 3%, respectively. CC-16 levels were
measured using a commercially available ELISA (Biovender, Candler, NC). The intra-assay
coefficient of variation was 4%. All analytes were measured in duplicate.
Statistical Analysis
Biomarkers were analyzed either continuously or using quartiles, based on fractional
polynomial fit plots evaluating the relationship between each biomarker and predicted
probabilities of PGD (16); as well as categorizing each biomarker into quartiles as a dummy
variable in logistic regression models with PGD as the outcome. We evaluated CC-16
stratified by diagnosis (IPF vs. non-IPF) based on our previous finding that diagnosis is an
effect modifier of the relationship between CC-16 and PGD (8, 17). We also analyzed each
biomarker stratified by presence of pulmonary hypertension (defined by mean PA pressure
(mPAP) >40) to obtain further information about mechanisms within this high-risk sub-
group. We performed a sensitivity analysis of the association of biomarkers by time of
collection, repeating the analyses in those subjects who had plasma collected at the time of
listing, defined as greater than 24 hours prior to transplantation.
We used multivariable logistic regression to evaluate the relationship between each
biomarker and PGD while evaluating for confounding using variables previously
demonstrated to be risk factors for PGD, including BMI, mPAP, transplant type, ischemic
time, FiO2 at reperfusion, female sex and parity, pre-transplant diagnosis, donor smoking
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(defined as any history of smoking) and use of cardiopulmonary bypass (18). Using a
prediction model previously developed (19) for PGD using bootstrap resampling methods,
which incorporated pre-transplant diagnosis, obesity, and pulmonary artery pressure, we
evaluated significant biomarkers for incremental predictive utility by comparing area under
the curve (AUC) for the model with an individual biomarker to the model without. A
likelihood ratio test was used to evaluate for significant differences in AUC. Multiple
imputation was used to account for missing data in the covariates (20). Imputation was not
used in either the exposure (biomarker) or outcome (grade of PGD) variables; the very few
individuals with missing biomarker values were excluded from analyses. P values of less
than 0.05 were considered significant. Analyses were performed using STATA version 12.0
(STATA Corp., College Station, TX).
Results
There were 714 subjects in the study, of which 130 (18%, 95% CI: 15%, 21%) developed
PGD. The majority of plasma samples were obtained at the time of transplantation, however,
there were 126 subjects (19%) who had samples collected more than 24 hours prior to
transplantation. In those subjects, plasma samples were collected at the time of listing. The
average time between collection and transplantation in those subjects was 80 ± 96 days.
Missing biomarker values (n=2) were due to assay failure.
Subjects with PGD more frequently received a lung from a smoking donor, were more
obese, and had IPF and PAH more often as a pre-transplant diagnosis (10). Additionally,
subjects with PGD had higher mPAP, more frequent RBC transfusions, and more frequent
use of cardiopulmonary bypass (Table 1). The percentage of missing data for each covariate
is listed in Table 1. There were no significant differences in plasma levels of sRAGE,
ICAM-1, IL-8, and Protein C between those with PGD and those without (Table 2).
Median plasma CC-16 levels were higher in subjects with PGD compared to those without
(10.1 (IQR: 5.2, 19) vs. 6.0 (IQR: 3.4, 12.8), p<0.001). We analyzed CC-16 categorically, in
quartiles, based on the relationship of CC-16 with predicted probability of PGD generated
from the fractional polynomial fit plot (Figure 1). There was an increased odds of PGD in
subjects in the third quartile of CC-16 (OR: 1.89, 95% CI: 1.08, 3.32, p=0.03) and the
highest quartile of CC-16 (OR: 2.35, 95% CI: 1.35, 4.08, p=0.002) compared to the lowest
quartile of CC-16. When we evaluated CC-16 and pre-transplant diagnosis (stratified as IPF
vs. non-IPF) we found that the highest quartile of CC-16 had more subjects with IPF
compared to other diagnoses (118 vs. 60, p<0.001). There was no detectable association
between CC-16 and PGD in subjects with IPF (OR for highest quartile of CC-16 1.38, 95%
CI: 0.43, 4.45, p=0.59). Plasma CC-16 levels were higher in subjects with PGD than without
in the sub-group of non-IPF subjects (Figure 2a and b). The association between CC-16 and
PGD was unchanged in subjects without IPF (OR for third quartile: 1.90 95% CI: 0.97, 3.72,
p=0.06 and highest quartile OR 2.87, 95% CI: 1.37, 6.01, p=0.005). In a multivariable
model with previously identified risk factors for PGD, the association between CC-16 and
PGD in non-IPF subjects remained (OR for third quartile: 2.16, 95% CI: 1.00, 4.63, p=
0.049 and for fourth quartile: 3.03, 95% CI: 1.26, 7.30, p=0.013) (Table 3).
Given the association between pre-operative plasma CC-16 and PGD, we evaluated CC-16
as a possible predictor for PGD in non-IPF subjects. First, we evaluated the predictive utility
of CC-16 alone, which had an AUC of 0.60. Then, based on a previous study, we analyzed
the predictive utility of pre-transplant diagnosis, BMI category and mean PA pressure as a
base model. The negative predictive value of this model was 93% and the positive predictive
value was 20%. With the addition of CC-16 to the model, there were no significant
improvements in the negative or positive predictive values (90% and 15%, respectively),
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despite statistically significant improvement in the AUC (0.72 for model with CC-16 vs.
0.70 for base clinical model, p=0.04). Therefore, although elevated pre-operative plasma
CC-16 is an independent risk factor and possible biomarker of PGD, it may not be clinically
useful in prediction of PGD when added to known clinical predictor variables.
In sensitivity analyses, the relationship between the biomarkers and PGD did not change
significantly by time of sample collection. In subjects who had samples collected at the time
of transplantation, the relationship between CC-16 and PGD was unchanged (OR for highest
quartile of CC-16: 2.07, 95% CI: 1.00, 4.31, p=0.05). In subjects who had samples collected
greater than 24 hours from the time of transplantation (n=174), there was no change in the
relationship between CC-16 and PGD (OR for the highest quartile of CC-16 was 3.8, 95%
CI: 1.19, 12.14, p=0.02). There were not enough subjects to perform a stratified analysis by
individual diagnosis category.
Discussion
In this study, we have demonstrated an association between plasma CC-16 levels measured
pre-operatively and PGD. This association was strongest in subjects without IPF as a pre-
transplant diagnosis, and in subjects in the highest quartile of plasma CC-16. The association
was independent of adjustment from multiple known confounding variables, indicating that
the level of epithelial injury, as represented by circulating CC-16 levels, may predispose to
PGD prior to the transplant procedure. Although CC-16 was not a good predictor of PGD,
we have demonstrated the utility of CC-16 as a pre-operative marker of PGD. This study
builds on our prior work evaluating biomarkers in PGD (5, 6, 8) by exclusively evaluating
the pre-operative timepoint in a large cohort of prospectively studied transplant recipients,
with adequate power to evaluate the role of biomarkers in pre-specified sub-groups.
CC-16 is secreted by epithelial cells in the distal respiratory tract and acts to protect the
integrity of the epithelial lining against inflammation and oxidant stress (21). In sarcoidosis,
CC-16 is a biomarker of parenchymal disease severity, with increased levels being reflective
of increasing parenchymal disease (15, 22). CC-16 has also been evaluated as a biomarker
of acute lung injury, and plasma levels measured at the time of injury are decreased
compared to other causes of pulmonary edema (23, 24). In our study, increased plasma
levels of CC-16 in the recipient prior to transplantation are associated with subsequent PGD.
The difference in directionality from ALI may be because our measurement was taken prior
to the development of lung injury, not during, indicating that pre-existing epithelial injury is
associated with subsequent graft dysfunction. It is possible that systemic up-regulation of
lung epithelial injury pathways prior to transplantation lead to an increased susceptibility of
PGD. Future investigation on the systemic immune effectors of these pathways in the post-
transplant period is important.
We found that the association was strongest in subjects without IPF as a pre-transplant
diagnosis. Overall, subjects with IPF had a significantly higher CC-16 level compared to
other pre-transplant diagnoses. The lack of association between CC-16 and PGD in IPF
subjects may be that subjects with IPF already had such a strong signal of epithelial injury
prior to transplantation that any subsequent injury related to PGD is difficult to detect as
levels in IPF patients are so high (25). Alternatively, a recent study demonstrated that COPD
patients with high levels of circulating inflammatory markers in a symptom-free period had
a greater number of exacerbations (26). It may be that patients with COPD and other non-
IPF diagnoses with high CC-16 levels are a sub-group of “exacerbators” that are at increased
risk for epithelial injury after transplant, and that relationship is washed out in IPF where
there are consistently high CC-16 levels in all patients.
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When added to a predictive model using clinical covariates, CC-16 only had a slight
increase in utility for predicting PGD. Our findings indicate that pre-operative CC-16 levels
are independently associated with PGD, and worthy of further study into the mechanism of
development of PGD in those subjects without IPF, although it has not been proven a useful
predictor of those who will go on to develop PGD when measured pre-operatively.
We were unable to demonstrate an association between Protein C, lL-8, and sRAGE at the
pre-operative timepoint and PGD. Protein C and sRAGE have established associations with
PGD at post-operative timepoint (5, 7) and IL-8 is a marker of ALI (27); IL-8 was recently
demonstrated to have good predictive utility for ALI when measured in the ED. Our
inability to detect an association between these biomarkers and the subsequent development
of PGD may be because these biomarkers reflect mechanisms that are activated by the
process of IRI, and not mechanisms that are active in the recipient prior to transplantation.
Additionally, a small proportion of our pre-operative biomarkers was measured at months
prior to transplantation, and may have diluted our ability to detect an association using these
biomarkers.
Our study has several limitations. First, not all of the plasma measurements were taken at the
same timepoint, so there may have been other confounding factors associated with the
earlier measurements. However, in sensitivity analyses, the association between CC-16 and
PGD was unchanged in subjects who had plasma measurements at the time of listing or at
the time of transplantation. This increases applicability of our findings, as the association
was still present with biomarkers measured early, it supports the hypothesis that there may
be time for potential interventions prior to transplantation. Second, we do not have available
data on concomitant immunosuppressant medications at the time of pre-operative blood
draws. Although prior studies have successfully measured these markers in the setting of
concomitant steroid use, little is known about the effect of immunosuppressants on human
plasma levels, thus residual confounding may account for some of our negative results (23,
28–30). Third, we used multiple imputation to account for missing data in the covariates;
however, missing data on clinical covariates were rare and we had no missing PGD grade
and minimal missing biomarker measurements within the cohort.
In conclusion, we have demonstrated an association between pre-operative levels of CC-16
and PGD in subjects without IPF as a pre-transplant diagnosis. This finding sheds light on
pre-transplant, potentially modifiable factors that may lead to PGD. Further research is
warranted focusing on the mechanisms of how recipient epithelial injury “primes” the lung
for subsequent PGD.
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PGD primary graft dysfunction
CC-16 club (clara) cell secretory protein
sRAGE soluble receptor for advanced glycation end product
ICAM-1 intracellular adhesion molecule-1
UNOS united network for organ sharing
IPF idiopathic pulmonary fibrosis
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mPAP mean pulmonary arterial pressure
COPD chronic obstructive pulmonary disease
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Relationship of CC-16 level to predicted probability of grade 3 PGD on day 2 or 3 using
fractional polynomial plot. The gray area describes the 95% confidence interval.
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Figure 2a: CC-16 levels in those with PGD and those without PGD in subjects without
Idiopathic Pulmonary Fibrosis (IPF) as a pre-transplant diagnosis. Figure 2b. CC-16 levels
in those with PGD and those without PGD in subjects with Idiopathic Pulmonary Fibrosis
(IPF) as a pre-transplant diagnosis. The horizontal line in the middle of each box indicates
the median, the top and bottom borders mark the 75th and 25th percentiles, respectively; and
the whiskers mark the 90th and 10th percentiles.
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Table 1
Univariate analysis of donor, recipient in peri-operative variables stratified by Primary Graft Dysfunction
(PGD) status. PGD is defined as grade 3 PGD on day 2 or 3 after lung transplantation. Continuous variables
are listed as mean ± standard deviation.
Covariate Number Imputed n (%) PGD (n=130) Non-PGD (n=584) p-value
Donor Variables
 Male Gender, n, (%) 2 (0.3) 71 (55) 341 (58) 0.43
 Age 7 (1) 35.4 ± 14.8 34.8 ± 14.1 0.70
 Mode of Death, n (%) 1 (<1) 0.87
  Trauma 49 (38) 238 (41)
  Stroke 56 (43) 235 (40)
  Anoxia 9 (7) 46 (8)
  Other 16 (12) 65 (11)
 Race, n (%) 9 (1) 0.66
  Caucasian 87 (67) 365 (63)
  African American 26 (20) 117 (20)
  Other 17 (13) 102 (17)
 Any smoking, yes 27 (4) 70 (54) 246 (43) 0.001
Recipient Variables
 Male Gender, n (%) 3 (<1) 73 (56) 311 (53) 0.55
 Age 6 (1) 52.1 ± 12.7 53.0 ± 12.8 0.47
 BMI 14 (2) 26.0 ± 4.7 24.6 ± 4.5 0.002
 BMI category, n (%) 0.008
  <18.5 11 (8) 59 (10)
  18.5–25 40 (31) 258 (44)
  25–30 52 (40) 196 (34)
  >30 27 (21) 71 (12)
 Pulmonary Diagnosis, n (%) 3 (<1) <0.001
  Chronic obstructive pulmonary disease 33 (26) 256 (44)
  Idiopathic pulmonary fibrosis 56 (43) 180 (31)
  Cystic Fibrosis 13 (10) 96 (16)
  Sarcoidosis (3) 3 (2) 15 (3)
  Pulmonary arterial hypertension (4) 13 (10) 15 (3)
  Other 12 (9) 22 (4)
 mPAP 136 (19) 35.0 ± 17.6 27.9 ± 10.2 <0.001
 mPAP severity category, n (%) <0.001
  <25 mmHg (normal) 41 (32) 253 (43)
  25–40 mmHg (mild) 45 (35) 271 (46)
  41–55 mmHg (moderate) 33 (25) 51 (9)
  >55 mmHg (severe) 11 (8) 9 (2)
 Race, n (%) 3 (<1) 0.018
  Caucasian 103 (79) 506 (87)
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Covariate Number Imputed n (%) PGD (n=130) Non-PGD (n=584) p-value
  African American 21 (16) 44 (8)
  Other 6 (5) 34 (6)
Operative Variables
 Ischemic time, min 22 (3) 329 ± 92.2 305 ± 92.3 0.008
 Transplant type, single, n (%) 4 (1) 39 (30) 190 (33) 0.58
 PRBC >1L, n (%) 0 (0) 46 (35) 124 (21) 0.002
 Cardiopulmonary bypass use, n (%) 4 (1) 78 (60) 196 (34) <0.001
BMI: Body mass index
mPAP: mean pulmonary artery pressure
PRBC: Packed red blood cells
Percentages may not exactly equal 100% because of rounding.
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Table 2
Median (interquartile range) pre-operative biomarker levels by PGD status. P values were calculated using the
Wilcoxon-rank sum test. The number of subjects with a valid biomarker measurement is listed next to the
biomarker.
Biomarker n PGD (n=130) Non-PGD (n=584) p-value
CC-16 (ng/mL) 712 10.1 (5.2, 19.0) 6.0 (3.4, 12.8) <0.001
sRAGE (pg/mL) 712 743.3 (438.9, 2030.8) 725.6 (391.7, 1462.6) 0.27
ICAM-1 (ng/mL) 714 223 (135, 333) 214 (137, 340) 0.97
IL-8 (pg/mL) 714 5.5 (3.3, 12.9) 5.3 (3, 10) 0.36
Protein C (% Control) 713 110 (77, 140) 105 (79, 134) 0.44
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Table 3
Univariate and multivariate results of CC-16 association with PGD in subjects without IPF as a pre-transplant
diagnosis
Variable Odds Ratio for third quartile of CC-16 p-value Odds ratio for fourth quartile of CC-16 p-value
CC-16 1.90 (0.97, 3.72) 0.06 2.87 (1.37, 6.01) 0.005
Adjusted for
 Body Mass Index 1.87 (0.95, 3.66) 0.07 2.83 (1.35, 5.94) 0.006
 Mean PA pressure 1.64 (0.82, 3.30) 0.16 2.58 (1.20, 5.55) 0.015
 Transplant type 2.05 (1.04, 4.05) 0.04 3.16 (1.49, 6.71) 0.003
 Ischemic time 1.88 (0.96, 3.69) 0.07 2.85 (1.36, 5.97) 0.005
 FiO2 at reperfusion 1.95 (0.99, 3.84) 0.05 2.82 (1.34, 5.95) 0.006
 Female sex and parity 1.99 (1.01, 3.92) 0.05 3.00 (1.42, 6.35) 0.004
 Packed red blood cell 2.05 (1.04, 4.08) 0.04 3.34 (1.56, 7.08) 0.002
 Donor Smoking 1.92 (0.98, 3.77) 0.06 2.90 (1.38, 6.07) 0.005
 Cardiopulmonary bypass 1.68 (0.84, 3.33) 0.14 2.31 (1.08, 4.94) 0.031
 Multivariable model* 2.16 (1.00, 4.63) 0.049 3.03 (1.26, 7.30) 0.013
*
Multivariable model includes BMI, mean PA pressure, transplant type, ischemic time, FiO2 at reperfusion, female sex and parity, PRBC, donor
smoking, and CBP
PA=pulmonary artery
FiO2=fraction of inspired oxygen
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